46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00458146 (ClinicalTrials.gov) | February 2007 | 5/4/2007 | A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis | A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 60mg of MM-093 Versus Placebo in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate | Rheumatoid Arthritis | Drug: MM-093 | Merrimack Pharmaceuticals | NULL | Completed | 18 Years | 80 Years | Both | 100 | Phase 2 | United States |
| 2 | NCT00105976 (ClinicalTrials.gov) | February 2005 | 18/3/2005 | Efficacy Study of MM-093 in Rheumatoid Arthritis Patients on Methotrexate (MTX) | A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels (2.5, 7.5 and 20 mg) of MM-093 in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate | Rheumatoid Arthritis | Drug: MM-093 | Merrimack Pharmaceuticals | NULL | Completed | 18 Years | 80 Years | Both | 260 | Phase 2 | United States |